In the last trading session, 1.08 million shares of the Silence Therapeutics Plc ADR (NASDAQ:SLN) were traded, and its beta was 1.05. Most recently the company’s share price was $4.16, and it changed around -$0.76 or -15.45% from the last close, which brings the market valuation of the company to $196.39M. SLN currently trades at a discount to its 52-week high of $27.72, offering almost -566.35% off that amount. The share price’s 52-week low was $4.82, which indicates that the current value has fallen by an impressive -15.87% since then. We note from Silence Therapeutics Plc ADR’s average daily trading volume that its 10-day average is 0.27 million shares, with the 3-month average coming to 577.70K.
Silence Therapeutics Plc ADR stock received a consensus recommendation rating of Buy, based on a mean score of 1.57. If we narrow it down even further, the data shows that 0 out of 7 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 0 recommended SLN as a Hold, whereas 3 deemed it a Buy, and 1 rated it as Underweight. Silence Therapeutics Plc ADR is expected to report earnings per share of -0.25 for the current quarter.
Silence Therapeutics Plc ADR (NASDAQ:SLN) trade information
Instantly SLN has showed a red trend with a performance of -15.45% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 6.29 on recent trading dayincreased the stock’s daily price by 33.86%. The company’s shares are currently down -39.53% year-to-date, but still down -25.85% over the last five days. On the other hand, Silence Therapeutics Plc ADR (NASDAQ:SLN) is -30.55% down in the 30-day period. We can see from the shorts that 0.35 million shares have been sold at a short interest cover period of 2.36 day(s).
The consensus price target as assigned by Wall Street analysts is $55, which translates to bulls needing to increase their stock price by 92.44% from its current value. Analyst projections state that SLN is forecast to be at a low of $49 and a high of $67.
Silence Therapeutics Plc ADR (SLN) estimates and forecasts
The year-over-year growth rate is expected to be -21.95%, down from the previous year.
Consensus estimates provided by 3 financial analysts predict the company will bring in an average of 3.73M in revenue for the current quarter. 3 analysts expect Silence Therapeutics Plc ADR to make 2.87M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 2.1M and 12.41M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 77.86%. Forecasts for the next quarter put sales growth at -76.89%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -6.72%. Silence Therapeutics Plc ADR earnings are expected to increase by -47.36% in 2025, but the outlook is negative -21.58% per year for the next five years.
SLN Dividends
Silence Therapeutics Plc ADR’s next quarterly earnings report is expected to be released in March.
Silence Therapeutics Plc ADR (NASDAQ:SLN)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 16.94% of Silence Therapeutics Plc ADR shares, and 62.77% of them are in the hands of institutional investors. The stock currently has a share float of 75.57%. Silence Therapeutics Plc ADR stock is held by 84.0 institutions, with TCG CROSSOVER MANAGEMENT, LLC being the largest institutional investor. By 2024-06-30, it held 7.4962% of the shares, which is about 3.3 million shares worth $62.61 million.
ARTAL GROUP S.A., with 6.323% or 2.78 million shares worth $52.81 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
